ERBB2 and renal pelvis/ureter urothelial carcinoma: Overall, the baseline characteristics demonstrated clinical heterogeneity, with a balanced distribution of HER2 expression and a predominance of combination immunotherapy, reflecting real-world treatment patterns for advanced UTUC.